SynthesisFrontiers in pharmacology2026
Unveiling the therapeutic profile of pomiferin: a meta-analysis of cytotoxicity and oxidative stress modulation in preclinical models.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pomiferin, a prenylated isoflavonoid from Methods: A systematic search in PubMed, Scopus, and Web of Science was conducted following PRISMA guidelines. A "mean-only" approach was used to manage within-study dependency and inconsistent variance reporting. Data were analysed with multilevel random-effects models and Cluster-Robust Variance Estimation (CR2). Results: The pooled geometric mean Conclusion: This meta-analysis demonstrates that Pomiferin is a context-dependent agent that modulates enzymatic defences, such as CAT, confirming its potential as a therapeutic candidate. It highlights the efficacy limits in resistant types, such as Glioma, and provides a quantitative basis for future research. This study consolidates diverse findings into a robust evidence base, serving as the first comprehensive meta-analysis of Pomiferin's biological activity and guiding future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.